Given the crucial involvement of JAK-STAT signaling in antigen presentation and T cell recruitment, completely inhibiting JAK1/2 activity is unlikely to enhance anti-tumor immunity or the response to ICI treatment. Here, SOAT1 is linked to neoplasm.